Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sunesis Pharmaceutic (SNSS)

Sunesis Pharmaceutic (SNSS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sunesis Pharmaceutic 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 USA

www.sunesis.com P: 650-266-3500 F: 650-266-3501

Description:

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.

Key Statistics

Overview:

Market Capitalization, $K 96,255
Shares Outstanding, K 18,093
Annual Sales, $ 2,070 K
Annual Net Income, $ -23,330 K
60-Month Beta 2.21
% of Insider Shareholders 4.22%
% of Institutional Shareholders 25.61%
Float, K 17,329
% Float 95.78%

Growth:

1-Year Return -42.17%
3-Year Return -92.40%
5-Year Return -87.33%
5-Year Revenue Growth -63.87%
5-Year Earnings Growth 94.08%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 03/09/21
Earnings Per Share ttm -1.39
EPS Growth vs. Prev Qtr 51.67%
EPS Growth vs. Prev Year 51.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-7 on 02/25/21

SNSS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -179.05%
Return-on-Assets % -72.27%
Profit Margin % -1,127.05%
Debt/Equity 0.00
Price/Sales 29.96
Price/Cash Flow N/A
Price/Book 5.09
Book Value/Share 0.00
Interest Coverage -44.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar